Question for written answer E-005235/2021 to the Commission Rule 138 Mathilde Androuët (ID)

Subject: Export of half of the COVID-19 vaccine doses produced in the EU

On 8 May, Ursula von der Leyen announced that, in order to meet Europe's needs, the Commission had signed a new supply contract with BioNTech-Pfizer for a total of 900 million new doses for 2021-2023, with the option for 900 million more, despite their soaring price¹. This has also prompted the Commission to take AstraZeneca to court in Belgium, demanding that they urgently deliver the 90 million doses that are missing under its contract with the EU before the end of June².

However, during the Conference on the Future of Europe, also held on 8 May, Emmanuel Macron praised the fact that Europe had exported 200 million of the 400 million doses of COVID-19 vaccines that it had produced since the beginning of the pandemic³.

It is perfectly conceivable for the EU to play its part in the global fight against the pandemic. Nevertheless, given the slow pace of vaccination in the EU owing to insufficient doses, which killed many Europeans and upset our socio-economic fabric, what is the Commission's response to those who argue that this generosity should have been delayed?

https://www.bfmtv.com/economie/entreprises/industries/vaccin-pfizer-bio-ntech-pourquoi-le-prix-des-doses-grimpe-pour-les-europeens AV-202105090078.html

https://www.capital.fr/entreprises-marches/astrazeneca-lue-reclame-en-justice-90-millions-de-vaccins-dici-fin-juin-sous-peine-dastreinte-1402840

https://www.lesechos.fr/monde/enjeux-internationaux/en-direct-samedi-8-mai-covid-le-point-sur-lepidemie-enfrance-et-dans-le-monde-1313561